Folate receptor dendritic cell vaccine for ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a personalized vaccine made from your own immune cells, designed to target a protein called folate receptor alpha found on many ovarian cancer cells. It is for people who have finished initial chemotherapy and have no signs of cancer remaining, to try to prevent it from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have stage 3 or 4 ovarian, fallopian tube, or primary peritoneal cancer that was mostly high-grade serous, endometrioid, or clear cell type
- You completed one round of platinum chemotherapy (5 to 9 cycles) within the last 4 to 12 weeks
- You had surgery to remove the uterus and both ovaries (if not done before)
- You do not have a BRCA1 or BRCA2 gene mutation
- You are willing to get a tetanus shot (if not received in the past year) and may need a central line placed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a new cancer vaccine therapy combined with pembrolizumab (an immunotherapy) to treat advanced, recurrent ovarian, fallopian tube, or primary peritoneal cancer. It may help your immune system recognize and attack the cancer, especially if your tumor has a specific target called FRα.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
This study looks at a marker called folate receptor alpha in tissue samples from people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. The goal is to see how common this marker is, which may help guide future treatment options.
This Phase 2 trial studies a maintenance vaccine (DCVAC/OvCa) given after standard first-line chemotherapy and surgery for certain advanced ovarian cancers. It aims to help keep the cancer from coming back for longer by boosting the body’s anti-cancer response.
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
This trial tests a personalized vaccine (NeoOVSV) made from your tumor’s unique markers (neoantigens). It’s for women with Stage II or III epithelial ovarian cancer who had successful surgery to remove all visible cancer. The goal is to see if the vaccine is safe and helps your immune system fight any remaining cancer cells.
Hear when a new Advanced Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.